Corcept Therapeutics (CORT) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Corcept Therapeutics Announces First Quarter 2015 Results and Provides Corporate Update
May 7, 2015 4:06 PM EDTMENLO PARK, CA -- (Marketwired) -- 05/07/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)
Per-share net loss in first quarter narrows to $0.05, from $0.14 in the same period last year First quarter revenue is $10.1 million, compared to $4.4 million in the first quarter 2014, a 129 percent increase $17.2 million generated from exercise of warrants Patient dosing underway in efficacy portion of Phase 1/2 trial of Korlym to treat triple-negative breast cancer (TNBC); results expected by the end of 2015 Next-generation selective GR antagonist CORT125134 is well-tolerated and functionally active in Phase 1 and is expected to enter Phase 2 in... More